HOME >> BIOLOGY >> NEWS
Promising preclinical results with live attenuated H5N1 vaccines

Several approaches are in progress to develop vaccines against the avian flu variety of the influenza virus. Kanta Subbarao (National Institutes of Health) and colleagues are working on live attenuated vaccines, which have the potential to elicit a strong, broad, and lasting immune response. As they now report in the international open-access medical journal PLoS Medicine, results from mice and ferrets (the rodent flu model of choice) are very encouraging and pave the way to testing these vaccines in human volunteers.

The researchers developed vaccines using 3 artificially constructed, weakened forms of the influenza virus. The 3 vaccine viruses were constructed using flu virus proteins other than H and N from artificially weakened (attenuated) strains of influenza. These were combined with H and N proteins from H5N1 viruses isolated from human cases during three different years: 2004, 2003, and 1997. They grew larger quantities of the resulting viruses in hen eggs, and tested the vaccines in chickens, ferrets, and mice.

In tests of safety, the study found that, unlike the natural viruses from which they were derived, the vaccine strains did not cause death when injected into the bloodstream of chickens, and did not even cause persistent infection when given through the birds' breathing passages. Similarly, while the natural viruses were lethal in mice at various doses, the vaccine strains did not cause death even at the highest dose. In ferrets, infection with the vaccine strains was limited to the upper respiratory tract, while the natural viruses spread eadily to the lungs.

In tests of protection, all mice that had received any of the 3 vaccines survived following injection with any of the natural viruses (so-called viral challenge), while unvaccinated mice died following viral challenge. This occurred even though standard blood tests could not detect a strong immune responses following a single dose of vaccine. Challenge virus was
'"/>

Contact: Andrew Hyde
press@plos.org
44-122-346-3330
Public Library of Science
11-Sep-2006


Page: 1 2

Related biology news :

1. Promising protein may prevent eye damage in premature babies
2. Tailored treatments: Promising designer drug provides new insight into cancer biology
3. Promising antiobesity drug fails to produce clinically meaningful weight loss
4. Promising new research on hereditary diseases
5. Promising cell protein may play role in infection and dry eye
6. Promising anti-TB compound finally can be synthesized with ease
7. Promising results in the battle against incurable ALS muscle disease
8. Promising new preventative treatment option for population of men at high risk of prostate cancer
9. Serica scientists win AOSSM Award for ACL (knee) tissue regeneration in preclinical study
10. Fatty spheres loaded with siRNA shrink ovarian cancer tumors in preclinical trial
11. Tramiprosate (Alzhemed) preclinical results published in Neurobiology of Aging

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/2/2020)... ... 02, 2020 , ... With the integration, the company will ... as medical grade plastic products to the world’s leading pharmaceutical, medical device, biologics, ... excited to bring even more advantages and convenience to our partners and supply ...
(Date:12/30/2019)... ... December 30, 2019 , ... It’s been quite a year ... its highest sales in 2019, having hosted a multitude of team-building events and cooking ... the company’s La Jolla-based venue, and the company has worked hard to accommodate the ...
(Date:12/18/2019)... ... 17, 2019 , ... Mitotech S.A, a Luxembourg-based clinical-stage biotechnology ... U.S. Phase 3 study VISTA-2 building on positive results of VISTA-1 clinical study ... severe Dry Eye Disease (DED). SkQ1 belongs to the class of cardiolipin peroxidation ...
Breaking Biology News(10 mins):
(Date:1/22/2020)... ... January 21, 2020 , ... ... Taylor as Southern Midwest Region Industrial and Institutional (I&I) Account Manager. Darrell will ... , Darrell brings over 30 years of sales experience working across ...
(Date:1/10/2020)... ... January 09, 2020 , ... ... today announced the acquisition of Cunesoft, a move that expands the company’s portfolio ... of life sciences companies. , Based in Munich, Germany, Cunesoft provides intelligent software ...
(Date:1/7/2020)... , ... January 07, 2020 , ... ... products and services, today announced the launch of its VivopureX™ recombinant mouse antibodies ... clones, many originally obtained from rats or hamsters, which Absolute Antibody has engineered ...
(Date:1/7/2020)... ... January 06, 2020 , ... ... second cohort of emerging biosciences ventures invited to participate in the annual program. ... develop fundable business plans and a professional network. All startups will receive an ...
Breaking Biology Technology:
Cached News: